Abstract 1414P
Background
The aim of this study was to observe the concurrent genetic profiles of EGFR-mutated advanced Chinese non-small cell lung cancer (NSCLC), as well as to analyze the effects of diverse concurrent genetic alterations on the prognosis in EGFR-mutated NSCLC treated in first-line with EGFR-TKI.
Methods
The CAPTRA-Lung (NCT03334864) database was used to retrieve 307 patients with advanced EGFR-mutated NSCLC between January 1, 2018 and January 1, 2022 in our institution. Of those, 103 patients were detected by next-generation sequencing (NGS) and the results showed other concurrent genetic alterations. We divided them into two cohorts: those who were sequenced with NGS at baseline were included in cohort 1, and those who received NGS after progression to first-line therapy were contained in cohort 2. The follow-up deadline was October 1, 2022.
Results
The following genes are found to be most frequent in the entire cohort: TP53 mutation (n = 64, 62.14%), EGFR amplification (n = 14, 13.59%), KRAS mutation (n = 13, 12.62%), PIK3CA mutation (n = 13, 12.62%), and DNMT3A mutation (n = 13, 12.62%). Most of the TP53 mutations have been identified in exons 5 (16/64), 6 (9/64), 7 (10/64), 8(9/64), etc. For KRAS mutations, G12V (4/13) and G12S (3/13) were the most common mutation types, and E545K (5/13) and H1047R (2/13) were the most frequently alterations observed in PIK3CA. Cohort 1 constituted 68 patients (mean [SD] age, 60.93 [9.051] years; 55.9% female). Multivariate analysis demonstrated that alterations in TP53 (HR 1.946, 95% CI 1.112-3.403; P = 0.020) and MET (HR 3.581, 95% CI 1.070-11.992; P = 0.039) were independently correlated to poor progression-free survival (PFS). Cohort 2 encompassed 35 patients (mean [SD] age, 56.80 [8.741] years; 71.4% female). Multifactorial analysis showed that TP53 mutation (HR 2.198, 95% CI 1.006-4.803; P = 0.048) and RB1 mutation (HR 8.798, 95% CI 1.604-48.269; P = 0.012) were independent risk factors for PFS with first-line targeted therapy.
Conclusions
This research added to the evidence that co-alterations such as TP53, MET, and RB1 are prospective prognostic biomarkers in NSCLC patients treated with EGFR-TKI.
Clinical trial identification
NCT03334864.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20